Follow us on Twitter
This page is updated frequently with new Fatty Acid-related patents. Subscribe to the Fatty Acid RSS feed to automatically get the update: related Fatty RSS feeds.
Subscribe to updates on this page: Fatty Acid RSS
|| List of recent Fatty Acid-related patents
| Crimped conjugated fiber and non-woven fabric comprising the fiber|
It is an object of the present invention to obtain crimped conjugated fibers having excellent crimp properties. The present invention provides a crimped conjugated fiber having a crimpable cross-sectional configuration, wherein a cross section of the fiber includes at least two portions: a portion (a) and a portion (b); the portion (a) includes an olefin polymer (a) and the portion (b) includes an olefin polymer (b); the olefin polymer (a) differs from the olefin polymer (b) in at least any one of mz/mw, melting point and mfr; and a specific fatty acid amide is added to the olefin polymer (a) and/or the olefin polymer (b).
| Method for producing oil containing highly unsaturated fatty acid using lipase|
A method for lowering content of a sterol in a highly unsaturated fatty acid-concentrated oil in a method to concentrate a highly unsaturated fatty acid by using a lipase reaction, may include removing the free form of the sterol from a raw material oil that includes a highly unsaturated fatty acid-containing glyceride prior to performing the lipase reaction; and thereafter concentrating the highly unsaturated fatty acid in the glyceride by using a lipase that is less reactive for the highly unsaturated fatty acid.. .
| Antistatic foam agent and antistatic master batch for producing foamed plastic items|
A foaming agent or a master batch comprising a foaming agent for producing hollow-shaped foamed plastics using a blow-molding process containing an antistatic agent. The antistatic agent can comprise a fatty acid ester, an ethoxylated amine, or an alkyl sulfonate.
| Polylactic acid composition and molded article thereof|
A method for producing a composition including polylactic acid and having excellent heat stability, especially moist heat stability, and a molded article thereof. The composition includes 100 parts by weight of a resin component (component a) which is composed of 5 to 100 wt % of polylactic acid (component a-α) and 95 to 0 wt % of a thermoplastic resin (component a-β), 0.001 to 5 parts by weight of a phosphono-fatty acid ester (component b), 0.01 to 5 parts by weight of a phosphate metal salt (component c), 0.001 to 2 parts by weight of at least one antioxidant (component d) selected from the group consisting of a phosphite-based compound, a phosphonite-based compound, a hindered phenol-based compound and a thioether-based compound, and 0.001 to 10 parts by weight of an end-sealing agent (component e)..
| Metabolic syndrome ameliorating agent|
A method for ameliorating metabolic syndrome may include administering, to a patient in need thereof, an effective amount of a monounsaturated fatty acid having 22 carbons or a salt or an ester thereof and/or an effective amount of a monounsaturated fatty acid having 20 carbons or a salt or an ester thereof.. .
| External preparation composition comprising fatty acid-based ionic liquid as active ingredient|
Disclosed is an external preparation composition having good transdermal absorbability. An external preparation composition having excellent transdermal absorbability can be produced by dissolving a medicinal substance or a salt thereof in a fatty acid-based ionic liquid to form a composite ionic composition of the medicinal substance.
| Heteroaryl substituted urea modulators of fatty acid amide hydrolase|
Certain heteroaryl-substituted piperidinyl and piperazinyl urea compounds are described, which are useful as faah inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (faah) activity, such as anxiety, pain, inflammation, sleep disorders, eating disorders, insulin resistance, diabetes, osteoporosis, and movement disorders (e.g., multiple sclerosis)..
| Method for treating neurotrauma|
The invention relates to a composition comprising: i) one or more of uridine and cytidine, or salts, phosphates, acyl derivatives or esters thereof; ii) a lipid fraction comprising at least one of docosahexaenoic acid (22:6; dha), eicosapentaenoic acid (20:5; epa) and docosapentaenoic acid (22:5; dpa), or esters thereof, in which the lipid fraction comprises less than 2 weight % of □-linolenic acid (ala), calculated on the weight of all fatty acids; iii) choline, or salts or esters thereof; for use in the prevention or treatment of neurotrauma, traumatic brain injury, cerebral palsy and spinal cord injury.. .
| Delta-9 desaturase used in the biosynthesis of polyunsaturated fatty acids|
The present invention provides novel fatty acid desaturases genes used for synthesis of polyunsaturated fatty acids, especially delta-9 desaturases (fads9-i). The present invention also provides nucleic acid sequence coding the above-described desaturases, expression vector of the above-described desaturases and recombinant microorganism expressing above-described desaturases..
| Confectionery coating fat with low saturated fat|
Disclosed are compositions for confectionery coating fat compositions, wherein the coatings exhibit good coating properties yet have very low saturated fat contents, very high unsaturated fat contents and low trans contents. The confectionery coating fat compositions of the invention can be used alone or in blends to have 35 to 80%, e.g., 70% or less, saturated fatty acids for preparing confectionery coating compositions comprising sugar and flavor that exhibit good snap.
| Solvent-free process for obtaining phospholipids and neutral enriched krill oils|
The invention discloses a new solvent-free process for obtaining phospholipids and neutral lipids enriched krill oils containing dha and epa poly-unsaturated fatty acids and astaxanthin. The process includes cooking fresh krill at high temperature—without agitation and or grinding; decanting the cooked krill for obtaining a partial de-fatted and de-watered solid and a liquid; squeezing the obtained solid to obtain a press liquid and a solid fraction; centrifuging the press liquid to obtain the phospholipids enriched krill oil; centrifuging of the decanter liquid obtained to obtain the neutral lipid enriched krill oil and stickwater..
| Sour gelled emulsions|
The invention relates to an orally administrable, sour-tasting chewable composition in unit dosage form comprising an oil-in-water emulsion in which the aqueous phase is gelled and comprises at least one physiologically acceptable acid and at least one buffering agent and in which the oil phase comprises a physiologically tolerable unsaturated fatty acid ester.. .
| Radiopaque iodinated products intended for use medical imaging and their methods|
Wherein ag1 represents an unsaturated (c8-c52) aliphatic hydrocarbon chain found in fatty acids having specific location of double bonds, the chain including at least one iodine atom directly linked to a carbon atom of a non-conjugated double bond by a covalent link, the second carbon atom of the double bond bearing a halogen atom different from a iodine atom, x represents a polyethylene glycol including 1 to 50 ethylene glycol groups, r represents a hydrogen atom or a group ag2 being identical to or different from ag1, ag1, x, r and ag2 being selected so that the amphiphilic compound has a hydrophilic/lipohilic balance included between 4 and 30.. .
| Inkjet ink composition and method for producing the same, inkjet recording method, pigment dispersion for inkjet ink and method for producing the same|
An inkjet ink composition includes (component a) c.i. Pigment yellow 180, (component b) a fatty acid amide compound, and (component c) a high molecular weight dispersant.
| Wax compositions and methods of preparing wax compositions|
Described are morphology stable wax compositions comprising the (trans)esterification product of a wax-forming composition comprising: (a) a triglyceride stock, a fatty acid stock, or a mixture thereof; and (b) a glycerol-based composition comprising glycerol, polyglycerol, or a mixture thereof. Methods of making the waxes are also described.
| Process for producing mixed esters of fatty acids as biofuels|
A process for producing mixed esters of fatty acids as biofuel or additive to a petroleum fuel for use in a compression ignition (ci) engine. The process preferably provides a partial transesterification of a mixture of fatty acid methyl esters with at least one alkyl alcohol containing 2 to 8 carbon atoms in the presence of a heterogeneous solid acid catalyst to produce a mixture of the fatty acid methyl esters and alkyl alcohol esters of the fatty acids..
| Process for producing biodiesel through lower molecular weight alcohol-targeted cavitation|
A method for producing fatty acid alkyl esters from biolipids through transesterification and/or esterification reactions uses a flow-through cavitation device for generating cavitation bubbles in a fluidic reaction medium. The fluidic medium is passed through sequential compartments in the cavitation device having varying diameters and inner surface features to create localized reductions in fluid pressure thus vaporizing volatile alcohols and creating an increased surface area and optimized conditions for the reaction to occur at the gas-liquid interface around the bubbles..
|Deodorized edible oil or fat with low levels of bound-mcpd and process of making using an inert gas|
A process for making a deodorized edible oil or fat having a low level of bound mcpd (monochloro propanediol esters) and/or low level of bound 3-mcpd is described. The process comprises a step of stripping the vegetable oil or fat with an inert gas.
|Self-emulsifying composition of omega3 fatty acid|
This invention provides a self-emulsifying composition comprising 50 to 95% by weight in total of at least one compound selected from the group consisting of ω3 polyunsaturated fatty acids and their pharmaceutically acceptable salts and esters; and 5 to 50% by weight of an emulsifier having a hydrophilic lipophilic balance of at least 10. The composition has no or reduced ethanol content, and exhibits excellent self-emulsifying property, dispersibility in the composition, emulsion stability, and absorption property.
|Usnic acid topical formulation|
Topical skin treatment formulation containing usnic acid or an usnate salt, dissolved in a solvent system comprising (i) dimethyl isosorbide; (ii) a c1 to c9 alkyl salicylate; and (iii) a glyceryl fatty acid ester. The solvent system may also comprise an alcohol, a polyoxyalkylene-based solvent, and/or a c1 to c4 alkyl glucose ester.
|Topical formulations and uses thereof|
Provided herein include formulations for topical administration, such as ophthalmic formulations, and methods of using such formulations. In some aspects and embodiments the formulations may include a polyoxyl lipid or fatty acid, and or a polyalkoxylated alcohol and may include nanomicelles.
An aqueous fabric conditioner composition comprising (a) from 2 to 9 wt % of a fabric softening active, by weight of the total composition, wherein the fabric softening active is an ester-linked quaternary ammonium compound having fatty acid chains comprising from 20 to 35 wt % of saturated c18 chains and from 20 to 35 wt % of monounsaturated c18 chains, by weight of total fatty acid chains; and (b) from 0.01 to 0.5 wt %, by weight of the total composition, of a floc prevention agent, which is a non-ionic alkoxylated material having an hlb value of from 8 to 18, wherein the aqueous fabric conditioner composition has a viscosity of greater than 50 cps, preferably from 55 to 200 cps as measured on a cup and bob viscometer; the viscosity being continuously measured under shear at 106 s″1 for 60 seconds, at 25° c. And wherein the composition leads to little or no floc formation upon addition to water..
|Liquid soaps with triclocarban|
An aqueous and liquid cleansing composition comprises a fatty acid soap, a salt of a lauryl ether sulfate surfactant that is present in an amount that is at least 50% of the weight of the fatty acid soap, a betaine surfactant that is present in an amount othat is at least 23% of the weight of the fatty acid soap, and at least 0.05% by weight of the composition of triclocarban. The lauryl ether sulfate and betaine surfactant in the specified amount in relation to the fatty acid soap amount keep the triclocarban from precipitating out of the composition..
|Stabilization of omega-3 fatty acids in saturated fat microparticles having low linoleic acid content|
An omega-3 fatty acid supplementation fat blend includes one part by weight of an omega-3 enriching oil containing epa and/or dha fatty acids that has been combined and diluted with at least one-half part by weight of a low linoleic acid content oxidatively stabilizing saturated fat. The omega-3 supplementation fat blend is incorporated into stabilized aqueous suspensions including beverages and foods..
|Method of modulating fatty acid mobilization and oxidation|
Methods of mobilizing fatty acids are disclosed.. .
|Fatty acid acylated amino acids for oral peptide delivery|
The present invention relates to fatty acid acylated amino acids (fa-aa's) acting as permeation enhancers for oral delivery of therapeutic macromolecules such as peptides and pharmaceutical compositions comprising such fa-aa's.. .
The present invention pertains to an antigenic formulation comprising a biological antigen, wherein the formulation comprises an oil containing as a principle constituent a fatty acid ester of eleostearic acid. The invention also pertains to the use of the said oil to manufacture an antigenic formulation..
|Pufa polyketide synthase systems and uses thereof|
Disclosed are the complete polyunsaturated fatty acid (pufa) polyketide synthase (pks) systems from schizochytrium, and biologically active fragments and homologues thereof. More particularly, this invention relates to nucleic acids encoding such pufa pks systems, to proteins and domains thereof that comprise such pufa pks systems, to genetically modified organisms (plants and microorganisms) comprising such pufa pks systems, and to methods of making and using the pufa pks systems disclosed herein.
|Eicosapentaenoic acid (epa) as polyunsaturated free fatty acid in its directly compressible powder form and process of isolation thereof|
The present invention provides eicosapentaenoic acid (epa) in its free fatty acid form and a process of isolation thereof from oils and fats of natural origin having eicosapentaenoic acid (epa) attached to triglycerides. The epa isolated using the process of the present invention is in free flowing powder form which is directly compressible.
|Vinylidene fluoride-based resin film, solar cell back sheet, and solar cell module|
A vinylidene fluoride-based resin film is prepared by blending a vinylidene fluoride resin, a methacrylate ester resin, a titanium oxide surface-treated with alumina, silica, and zirconia, and a polyethylene glycol fatty acid ester and/or the derivative thereof at a certain ratio. Used then was a surface-treated titanium oxide with alumina, silica, and zirconia, having a total deposited amount of alumina, silica, and zirconia of 5 to 15 mass % and a deposited amount of zirconia of 0.5 mass % or more and less than 2.0 mass %..
|Copolyesters having repeat units derived from w-hydroxy fatty acids|
The present invention relates to aliphatic or aliphatic-aromatic polyesters and copolyesters comprised of biobased ω-hydroxyfatty acids or derivatives thereof, processes for the preparation thereof, and compositions thereof having improved properties. The copolyesters of the present invention may also contain additional components that can be selected from aliphatic or aromatic diacids, diols and hydroxyacids obtained from synthetic and natural sources.
|Transnasal anticonvulsive pharmaceutical composition comprising poorly soluble anticonvulsant|
There is provided a transnasal anticonvulsive pharmaceutical composition including a poorly soluble anticonvulsant. The anticonvulsive pharmaceutical composition comprising a poorly soluble anticonvulsant as an active component, which is transnasally spray-administered, comprises diethylene glycol monoethyl ether and fatty acid ester, wherein the fatty acid ester is selected from the group consisting of caprylocaproyl polyoxylglyceride, isopropyl palmitate, oleoyl polyoxylglyceride, sorbitan monolaurate 20, methyl laurate, ethyl laurate, and polysorbate 20.
|Vaginal compositions based on alkyl polyglucosides|
Compounds based on alkyl polyglycosides for use in the treatment of streptococcus agalactiae infections and other pathogens are provided. Such compounds may belong to the class of alkyl glucosides or alkyl polyglucosides.
|Biologically active complex and its preparation|
A biologically active complex comprising either a polypeptide having the sequence of a variant of a naturally occurring protein, wherein said polypeptide is at least partially unfolded as compared to the said naturally occurring protein; or a peptide of up to 50 amino acids, for instance a fragment of the naturally occurring protein or a variant thereof; and a pharmaceutically acceptable salt of a fatty acid or lipid. The complexes of the invention demonstrate a novel mode of action, that gives rise to opportunities for the development of further active agents and screening methods..
|Micoorganisms and methods for the production of fatty acids and fatty acid derived products|
This invention relates to metabolically engineered microorganism strains, such as bacterial strains, in which there is an increased utilization of malonyl-coa for production of a fatty acid or fatty acid derived product, wherein the modified microorganism produces fatty acyl-coa intermediates via a malonyl-coa dependent but malonyl-acp independent mechanism. .
|Delta-15 desaturases suitable for altering levels of polyunsaturated fatty acids in oilseed plants and oleaginous yeast|
The present invention relates to fungal Δ-15 fatty acid desaturases that are able to catalyze the conversion of linoleic acid (18:2, la) to alpha-linolenic acid (18:3, ala). Nucleic acid sequences encoding the desaturases, nucleic acid sequences which hybridize thereto, dna constructs comprising the desaturase genes, and recombinant host plants and microorganisms expressing increased levels of the desaturases are described.
|Encapsulated acid, method for the preparation thereof, and chewing gum comprising same|
Delayed release in chewing gum of a food-grade acid, is provided by encapsulating the food-grade acid in specific amounts of a poly(vinyl acetate) and a fatty acid salt. When incorporated into a chewing gum, the food-grade acid encapsulated in poly(vinyl acetate) and fatty acid salt provides a more delayed release of a sour flavor than food-grade acid encapsulated in poly(vinyl acetate) alone..
|Stabilized formulation comprising omega-3 fatty acids and use of the fatty acids for skin care and/or wound care|
A stabilized formulation for skin care, wound care and/or other tissue healing applications and methods for making the same is described. The stabilized formulation stabilizes omega-3 polyunsaturated fatty acids and is constituted of the omega-3 polyunsaturated fatty acids in combination with tocopherol (vitamin e), ascorbic acid (vitamin c), herb extract, and a fat-soluble antioxidant.
|Disorders implicating pufa oxidation|
Some aspects of the invention provide for a method of treating hepatic disorders, lipidemias and cardiac-related risk factors using polyunsaturated fatty acids which are modified in certain positions to attenuate oxidative damage by reactive oxygen species (ros) and/or suppress the rate of formation of reactive products and toxic compounds.. .
|Heterogeneous catalysts for transesterification of triglycerides and preparation methods of same|
Method for transesterification of fatty acid esters. The method includes contacting (i) a catalyst comprising at least one of barium oxide and apatite with (ii) a reaction medium comprising at least one of vegetable oil and fats..
|Plant derived seed extract rich in essentially fatty acids derived from salvia hispanica l. seed: composition of matter, manufacturing process and use|
A salvia hispanica l. Derived seed oil extract composition of matter containing from 60-88% pufas in a ratio of from 3.1:1-3.3:1 of ala to la, 4-10% of c-18 mono-unsaturated fatty acid, 1-5% of c-18 saturated fatty acid and 4-8% of c-16 saturated fatty acid in a mixed triglyceride form stable at room temperature of 12-24 months containing a mixture of selected antioxidants..
|Composition and method for treatment of diabetes|
The present invention relates to a method of treating diabetes type ii by delivery of butyric acid, bile acid, long chain fatty acid or glutamine to the colon by bypassing the upper digestive tract. The composition is combined either by the same or different route of administration with a dpp-iv inhibitor such as vildagliptin..
|Tetracyclic inhibitors of fatty acid amide hydrolase|
Certain tetracyclic compounds are described, which may be used in pharmaceutical compositions and methods for treating disease states, disorders, and conditions mediated by fatty acid amide hydrolase (faah) activity. Thus, the compounds may be administered to treat, e.g., anxiety, pain, inflammation, sleep disorders, eating disorders, or movement disorders (such as multiple sclerosis)..
A composition is disclosed herein comprising from about 0.001% to about 0.4% cyclosporin a, castor oil, and a surfactant selected from the group consisting of alcohol ethoxylates, alcohols, alkyl glycosides, alkyl polyglycosides, alkylphenol ethoxylates, amine oxides, block polymers, carboxylated alcohol or alkylphenol ethoxylates, carboxylic acids/fatty acids, cellulose derivatives, ethoxylated alcohols, ethoxylated alkylphenols, ethoxylated aryl phenols, ethoxylated fatty acids, ethoxylated fatty acids, ethoxylated fatty esters and oils, fatty alcohols, fatty esters, glycol esters, lanolin-based derivatives, lecithin and lecithin derivatives, lignin and lignin derivatives, methyl esters, monoglycerides and derivatives, phosphalipids, polyacrylic acids, polyethylene glycols, polyethylene oxide-polypropylene oxide copolymers, polyethylene oxides, polymeric surfactants, polypropylene oxides, propoxylated alcohols, propoxylated alkyl phenols, propoxylated fatty acids, protein-based surfactants, sarcosine derivatives, silicone-based surfactants, sorbitan derivatives, stearates, sucrose and glucose esters and derivatives, and combinations thereof.. .
|Methods for treating and preventing cardiac dysfunction in septic shock|
Cardiac dysfunction during sepsis is due, at least in part, to cardiac energy deficiency. It has been discovered that lipopolysaccharide (lps)-mediated cardiac dysfunction is prevented or treated by treatments that improve fa oxidation (fao), despite the persistence of inflammation.
Popular terms: [SEARCH]
Fatty Acid topics: Fatty Acid, Fatty Acids, Hydrocarbon, Carbon Dioxide, Internal Combustion Engine, Alkali Metal, Unsaturated Fat, Saturated Fat, Fatty Acid Amide, Carbon Atoms, Crystallize, Crystallin, Chemical Reaction, Carboxylic Acid, Electrolytic Cell
Follow us on Twitter
This listing is a sample listing of patents related to Fatty Acid for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Fatty Acid with additional patents listed. Browse our RSS directory or Search for other possible listings.